Mind Medicine (MNMD)
NASDAQ:MNMD
Holding MNMD?
Track your performance easily

Mind Medicine (MNMD) Income Statement

1,392 Followers

Mind Medicine Income Statement

Last quarter (Q2 2024), Mind Medicine's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Mind Medicine's net income was $―. See Mind Medicine’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
-----
Cost of Revenue
----$ 3.84M
Gross Profit
----$ -3.84M
Operating Expense
$ 66.02M$ 93.87M$ 66.33M$ 93.85M$ 33.03M
Operating Income
$ -66.08M$ -93.92M$ -66.33M$ -93.85M$ -33.03M
Net Non Operating Interest Income Expense
$ 3.29M$ 4.66M$ 1.50M$ -359.00K$ -164.00K
Other Income Expense
$ 19.67M$ -6.53M$ 7.84M$ -106.00K$ 873.00K
Pretax Income
$ -96.19M$ -95.73M$ -72.49M$ -94.19M$ -34.20M
Tax Provision
---$ -1.16M-
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -96.19M$ -95.73M$ -72.49M$ -93.04M$ -34.20M
Basic EPS
$ -2.18$ -2.44$ -1.84$ -0.23$ -1.95
Diluted EPS
$ -2.18$ -2.44$ -1.84$ -0.23$ -1.95
Basic Average Shares
$ 127.84M$ 39.16M$ 30.86M$ 410.66M$ 17.75M
Diluted Average Shares
$ 127.84M$ 39.16M$ 30.86M$ 410.66M$ 17.75M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 43.87M$ 93.87M$ 66.33M--
Net Income From Continuing And Discontinued Operation
$ -96.19M$ -95.73M$ -72.49M$ -93.04M$ -34.20M
Normalized Income
$ -84.57M$ -70.36M$ -53.28M$ -95.35M$ -25.13M
Interest Expense
-----
EBIT
$ -95.75M$ -95.73M$ -72.49M$ -93.85M$ -34.03M
EBITDA
$ -93.64M$ -92.57M$ -69.31M$ -91.24M$ -34.03M
Currency in USD

Mind Medicine Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis